Date :
Place : United States of America, Philadelphia
Website :https://cii.dryfta.com/eid/357/pid/47
Contact Person:CHI
Description:
Commercializing breakthrough immune-oncology therapeutics is becoming increasingly challenging due to funding limitations, high cost and attrition rates in the clinic, regulatory uncertainties, persistent therapeutic safety and efficacy concerns, andDeadline for abstracts/proposals : 11th August 2025
Organized By :
Keynote Speakers :
Check the event website for more details.